Advertisement · 728 × 90
#
Hashtag
#WGRX
Advertisement · 728 × 90
Preview
Wellgistics Management Converts $2 Million in Deferred Compensation into Equity at $0.20 per Share TAMPA, FL / ACCESS Newswire / March 19, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart

#WGRX Wellgistics Management Converts $2 Million in Deferred Compensation into Equity at $0.20 per Share

www.stocktitan.net/news/WGRX/wellgistics-ma...

0 0 0 0
Preview
Wellgistics President Releases Letter to Shareholder on Emerging Patient Care-Centric Strategic Direction Wellgistics (NASDAQ:WGRX) said its President & Interim-CEO outlined a strategic pivot toward selling prescription drugs directly to patients via its online pharmacy and expanding its EinsteinRx AI platform beyond dispensing optimization.The company cited exclusive technology licensing for PharmacyChain™, partnerships including NFL Alumni Health and Tollo Health, and plans to deploy telemedicine, diagnostic testing, and benefits-verification tools.

#WGRX Wellgistics President Releases Letter to Shareholder on Emerging Patient Care-Centric Strategic Direction

www.stocktitan.net/news/WGRX/wellgistics-pr...

0 0 0 0
Preview
Wellgistics Health Provides 2026 Corporate Outlook Wellgistics Health (NASDAQ:WGRX) provided its 2026 corporate outlook on January 7, 2026, announcing initial integration of its proprietary AI prescription optimization platform EinsteinRx into pharmacy point-of-sale systems and an onboarding target for its Wellgistics Pharmacy Network.The company said it currently serves > 6,500 independent pharmacies, is optimizing onboarding to reduce friction, and aims to onboard up to 500 pharmacies per month by year-end 2026. Wellgistics plans to expand manufacturer relationships (starting with SGLT-2 drug Brenzavvy®) to cover diabetes, GLP-1/weight-loss and cardiometabolic patient groups. PharmacyChain™ smart-contract resource assessment is ongoing.

#WGRX Wellgistics Health Provides 2026 Corporate Outlook

www.stocktitan.net/news/WGRX/wellgistics-he...

0 0 0 0
Preview
Wellgistics Health Announces Launch of Diabetes Drug Brenzavvy(R) to Wellgistics Pharmacy Network Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are uninsured and underinsured and whose out-of-pocket costs exceed Brenzavvy's cash priceProprietary EinsteinRx™ artificial intelligence pharmacy platform empowers the 6,500+

#WGRX Wellgistics Health Announces Launch of Diabetes Drug Brenzavvy(R) to Wellgistics Pharmacy Network

www.stocktitan.net/news/WGRX/wellgistics-he...

0 0 0 0
Preview
Wellgistics Health Announces that it will Distribute a Dream Bowl 2026 Meme Coin to Wellgistics Health Stockholders Wellgistics Health (NASDAQ:WGRX) announced a 1-for-1 distribution of the Dream Bowl 2026 Meme Coin to shareholders of record on December 19, 2025. The ex-dividend date is December 20, 2025. Shareholders will receive one meme coin for each share owned on the record date, with a distribution to occur on or after December 20, 2025 and within 30 days following the record date in coordination with DataVault AI (NASDAQ:DVLT).The digital collectible embeds ticketing and event details and will be airdropped to shareholder wallets after holders provide wallet information via notices coordinated with the transfer agent. The Dream Bowl event is scheduled for January 11, 2026 at AT&T Stadium in Dallas, Texas.

#WGRX Wellgistics Health Announces that it will Distribute a Dream Bowl 2026 Meme Coin to Wellgistics Health Stockholders

www.stocktitan.net/news/WGRX/wellgistics-he...

0 0 0 0
Preview
Wellgistics Health Reports Third Quarter 2025 Financial Results and Provides Business Update Wellgistics Health (NASDAQ:WGRX) reported third quarter 2025 results and provided a business update on November 20, 2025. The company recorded a net operating loss of $33.878M in Q3 2025 versus $1.867M in Q3 2024, and net loss per share $0.46 on 74.379M weighted average shares (vs $0.04 on 48.403M).Management highlighted the completion of the EinsteinRx AI pharmacy hub software and a sales focus on launching Brenzavvy for the Type 2 diabetes market. The company expects a GLP-1 side-effect product to launch in Q1 2026 and is in advanced discussions to license blockchain smart-contract IP with DataVault AI in Q4 2025 or Q1 2026.

#WGRX Wellgistics Health Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/WGRX/wellgistics-he...

0 0 0 0
Preview
Wellgistics Health to Distribute Tollo Health GLP-1 Companion Muscle Loss Medical Food to Pharmacies & Physicians Wellgistics Health (NASDAQ:WGRX) expanded distribution with Tollo Health to offer a branded GLP-1 companion muscle-loss medical food to its 6,500+ independent pharmacy network and physicians, positioned as an adjunct to GLP-1 therapies to mitigate muscle loss during and after treatment.The company also added 3CL protease inhibitor Tollovid® to its galectin 1 & 3 inhibitor medical food Galectovid™, creating a natural antiviral combination aimed at Long COVID. The release cites a GLP-1 muscle-loss market of $53B today and an expected $156B by 2030.

#WGRX Wellgistics Health to Distribute Tollo Health GLP-1 Companion Muscle Loss Medical Food to Pharmacies & Physicians

www.stocktitan.net/news/WGRX/wellgistics-he...

0 0 0 0
Preview
Wellgistics Health Launches EinsteinRx as the Premier AI Prescription Management Hub Solution to Integrate Physical and Technology Healthcare Infrastructure Wellgistics Health (NASDAQ:WGRX) launched EinsteinRx, a prescription management hub to integrate physical and technology healthcare infrastructure across physicians, an in-house pharmacy and a >6,500 independent pharmacy network.The platform links manufacturing, insurance, patient data, nutritional guidance and fulfillment, and the company said it expects to begin onboarding new payer clients in Q4 2025. Wellgistics positions EinsteinRx to support its PharmacyChain™ smart contracts and access the $634 billion U.S. prescription drug market.

#WGRX Wellgistics Health Launches EinsteinRx as the Premier AI Prescription Management Hub Solution to Integrate Physical and Technology Healthcare Infrastructure

www.stocktitan.net/news/WGRX/wellgistics-he...

0 0 0 0
Preview
Wellgistics Health Enters into LOI to Acquire Kare Rx Hub Wellgistics Health (NASDAQ: WGRX) entered a non-binding letter of intent to acquire Kare Rx Hub, an AI-based digital pharmacy hub owned by Dr. Kiran Patel, in an all-stock deal expected to close by January 31, 2026. KareRx contributes a plug-and-play telemedicine pharmacy-support vertical, over 500 physician-provider relationships, >200 independent pharmacy relationships, and three manufacturer relationships. Management cites integration with a patent-protected blockchain platform via an emerging relationship with DataVault AI. The acquisition targets the expanding telemedicine remote dispensing market, projected to grow from $6.7B in 2025 to $13.57B by 2032 according to Fortune Business Insights.

#WGRX Wellgistics Health Enters into LOI to Acquire Kare Rx Hub

www.stocktitan.net/news/WGRX/wellgistics-he...

0 0 0 0

NEWS: ( NASDAQ: #WGRX ) AI Plus Health Plus Blockchain Deal Makes Wellgistics Health, Inc. (NASDAQ: WGRX) Top Nasdaq Gainer

0 0 0 0

News; ( NASDAQ: #WGRX ) Wellgistics stock's 200% rally on blockchain update is more hype than substance

0 0 0 0

BREAKING NEWS: ( NASDAQ: #WGRX ) Wall Street's AI and Infrastructure Trio Set the Tone

0 0 0 0
Video

📢 Stocks Trending NOW: #INTC #PG #DECK #SCNX #WGRX #GNTA #QLGN #VIVK #ITGR #GD

0 0 0 0
Preview
Wellgistics Health Announces Executive Management and Board Changes Wellgistics Health (NASDAQ:WGRX) announced executive and board changes on October 13, 2025. Prashant Patel, RPh, was re-appointed as President, Interim-CEO and board member after resigning in August 2025. Eric Sherb was named Interim-CFO. New directors Donald Fell, Steven D. Lee, and Howard Doss joined the board; Doss will serve as Audit Committee Chairman. Concurrent departures include CEO Brian Norton, CFO Mark DiSiena, COO Tony Madsen, and directors Rebecca Shanahan and Michael Peterson. The company stated leadership changes will refocus operations, rationalize the portfolio, and pursue pharmacy-centered revenue and AI strategies.

#WGRX Wellgistics Health Announces Executive Management and Board Changes

www.stocktitan.net/news/WGRX/wellgistics-he...

0 0 0 0
Preview
$5 Million Stock Offering: Wellgistics Health Raises Capital for AI-Powered Pharma Distribution Growth Pharma tech firm Wellgistics Health (NASDAQ:WGRX) offers 7.14M shares with warrants at $0.70/share. Proceeds to fund operations, R&D, and acquisitions. Closing expected Sept 29.

#WGRX Wellgistics Health Announces Pricing of $5 Million Public Offering

www.stocktitan.net/news/WGRX/wellgistics-he...

0 0 0 0

JUST IN: ( NASDAQ: #WGRX ) Wellgistics Health Introduces HubRx AI: Advancing the AI-Powered Prescription Ecosystem

0 0 0 0
Preview
$800B Prescription Market Disruption: Wellgistics Health's New AI Platform Aims to Eliminate $30B Annual Waste Wellgistics Health introduces AI-powered prescription hub platform integrating with major LLMs. Platform targets $5.7B hub services market by 2030, aims to reduce $30B annual healthcare waste.

#WGRX Wellgistics Health Introduces HubRx AI: Advancing the AI-Powered Prescription Ecosystem

www.stocktitan.net/news/WGRX/wellgistics-he...

0 0 0 0

BREAKING NEWS: ( NASDAQ: #WGRX ) US Companies Moving the Markets, Morning edition <br>Mon, Aug 25, 2025 as of 10.00 am ET

0 0 0 0
Preview
Healthcare Tech Leader Wellgistics Health Expands 6,500-Pharmacy Network, Reports Growth After IPO Pharmaceutical distribution tech firm reports $18.65M H1 revenue, converts $10.1M debt to equity. Network spans 6,500 pharmacies, 200 manufacturers. Advancing AI-driven prescription routing.

#WGRX Wellgistics Health Achieves Stability in First-Half 2025 and Executes Growth Initiatives

www.stocktitan.net/news/WGRX/wellgistics-he...

0 0 0 0

Wellgistics Health, a prescription drug distributor, has deployed Ripple's XRP Ledger in 6,500 U.S. pharmacies, making it the largest blockchain project in the U.S. healthcare sector.

#WGRX

0 0 0 0
Preview
Wellgistics Health Ditches ELOC as AI-Powered Pharmacy Platform Gains Traction Pharma tech company terminates equity purchase agreement amid strong network expansion and AI platform adoption. Shifts to accretive financing for next growth phase. Learn more.

#WGRX Wellgistics Health Terminates Equity Line of Credit to Further Support Growth Strategy

www.stocktitan.net/news/WGRX/wellgistics-he...

0 0 0 0
Preview
Healthcare Supply Chain Gets Crypto Upgrade: Wellgistics Brings XRP Payments to Independent Pharmacies Wellgistics Health introduces blockchain-based payment system for prescription drug purchases, promising instant settlements and lower fees. Platform targets 6,500+ pharmacies. Learn more.

#WGRX Wellgistics Health (NASDAQ: WGRX) Launches XRP Payment Program for Independent Pharmacies

www.stocktitan.net/news/WGRX/wellgistics-he...

0 0 0 0
Preview
$8.1M Debt-to-Equity Deal Powers Wellgistics Health's Expansion Plan in Pharmaceutical Distribution Strategic debt conversion unlocks improved capital access and competitive advantages. See how this $8.1M deal transforms Wellgistics Health's pharmaceutical distribution capabilities. Learn more.

#WGRX Wellgistics Health Converts $8.1M Debt to Equity

www.stocktitan.net/news/WGRX/wellgistics-he...

0 0 0 0
SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Tue Jul 22nd - #OPEN #PLUG #RR #SBET #SEDG #CIFR #WGRX #WRD #DNN #REPL #LUNR #IQ #FFAI #ESPR #DNUT #DFLI #CERS #CAAS #BTQQF #AOI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0
Preview
Wellgistics Health Reports 36% Revenue Growth in Q1 2025 as Manufacturer Access and Pharmacy Onboarding Accelerate Wellgistics Health (NASDAQ:WGRX) reported strong Q1 2025 financial results, with revenue reaching $10.86 million, representing a 36% year-over-year growth on a pro forma basis compared to $7.97 million in Q1 2024. The company demonstrated significant operational progress by registering 354 new pharmacies in the quarter, with approximately two-thirds already placing orders.Under CEO Brian Norton's leadership, Wellgistics Health is expanding its manufacturer relationships, broadening its product portfolio, and enhancing its technology infrastructure, including the planned expansion of its Peek platform. The company is also developing new hub service capabilities to support its next growth phase. Chairman Suren Ajjarapu highlighted the company's strategic use of financial tools like ELOC to support growth initiatives.

#WGRX Wellgistics Health Reports 36% Revenue Growth in Q1 2025 as Manufacturer Access and Pharmacy Onboarding Accelerate

www.stocktitan.net/news/WGRX/wellgistics-he...

0 0 0 0